Taiwan-based vaccine maker Medigen will conduct a Phase 3 clinical trial for its COVID-19 vaccine in Europe once it has received approval from European authorities, which would help pave the way for its entry into European and other international markets, the company announced Wednesday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Cross-Strait
Taiwan's opposition questions Xiaohongshu block as politically motivated
12/05/2025 10:15 PM - Business
Taiwan's Hon Hai reports highest sales for November
12/05/2025 08:57 PM - Business
Taiwan's inflation below 2% alert for 7th straight month in November
12/05/2025 08:30 PM - Society
Taiwan to end food-waste incineration by end of 2027
12/05/2025 08:29 PM - Politics
Lai praises bipartisan U.S. support for Taiwan Assurance Implementation Act
12/05/2025 08:04 PM